Potential antileukemic effect of gamma delta T cells in acute lymphoblastic leukemia.

Abstract:

:The immune response to leukemia is poorly understood. We postulated that nonmalignant T lymphocytes remaining within bone marrow from children with newly diagnosed ALL could be involved in this immune response. T lymphocytes which expressed gamma delta TCR comprised less than 1% of ALL marrow cells. A preferential outgrowth of gamma delta T cells within the CD3 population was observed when marrow cells were cultured with IL-2 alone or with stimulating feeder cells. These results, obtained in a series of 14 patients with precursor B-ALL, were significantly different when compared with expansions from normal marrow cells. In one patient, the clones established from the expanded population displayed different patterns of cytotoxicity against tumoral targets of the B cell lineage. Some clones expressing the TCR V delta 1 segment showed cytotoxic activity against a cell line derived from a pre-B ALL without activity against a LAK-sensitive B cell line. Using PCR amplification, one such clone was detected at high frequency, in the primary expansion of ALL marrow cells. These results suggest a prior activation in vivo of some gamma delta T cells by leukemic cells and provide some evidence on the role of these subsets in the immune response to leukemia.

journal_name

Leukemia

journal_title

Leukemia

authors

Duval M,Yotnda P,Bensussan A,Oudhiri N,Guidal C,Rohrlich P,Boumsell L,Grandchamp B,Vilmer E

subject

Has Abstract

pub_date

1995-05-01 00:00:00

pages

863-8

issue

5

eissn

0887-6924

issn

1476-5551

journal_volume

9

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.

    abstract::Cladribine has been reported to have little activity in fludarabine- refractory chronic lymphocytic leukemia (CLL). We sought to determine whether resistance to therapy with cladribine in fludarabine-refractory CLL patients represented primary drug resistance or the inability to tolerate the myelosuppression associate...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1038/sj.leu.2402752

    authors: Byrd JC,Peterson B,Piro L,Saven A,Vardiman JW,Larson RA,Schiffer C

    更新日期:2003-02-01 00:00:00

  • Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients.

    abstract::The serine/threonine kinase Akt, a downstream effector of phosphatidylinositol 3-kinase (PI3K), is known to play an important role in antiapoptotic signaling and has been implicated in the aggressiveness of a number of different human cancers including acute myeloid leukemia (AML). The progression of myelodysplastic s...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404057

    authors: Nyåkern M,Tazzari PL,Finelli C,Bosi C,Follo MY,Grafone T,Piccaluga PP,Martinelli G,Cocco L,Martelli AM

    更新日期:2006-02-01 00:00:00

  • Expression of human CSF-1 receptor induces CSF-1-dependent proliferation in murine myeloid but not in T-lymphoid cells.

    abstract::The receptor for human macrophage colony stimulating factor (CSF-1R) was introduced into hematopoietic cell lines of myeloid and T-lymphoid origin, both of which normally do not express the CSF-1R. Infection of an interleukin-3 (IL-3)-dependent mouse myeloid cell line (FDC-P1) with a high titer retroviral vector expre...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: von Rüden T,Mouchiroud G,Bourette RP,Ouazana R,Blanchet JP,Wagner EF

    更新日期:1991-01-01 00:00:00

  • Role of catalase in monocytic differentiation of U937 cells by TPA: hydrogen peroxide as a second messenger.

    abstract::Human promonocytic cell line U937 cells can be induced to differentiate into macrophages by treatment with 12-O-tetradecanoylphorbol-13-acetate (TPA). TPA treatment induced the expression of the monocytic differentiation markers CD11b and CD36, with concomitant morphological changes. Moreover, TPA enhanced reactive ox...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2008.353

    authors: Yamamoto T,Sakaguchi N,Hachiya M,Nakayama F,Yamakawa M,Akashi M

    更新日期:2009-04-01 00:00:00

  • Cellular and molecular studies on the early stages of human hematopoietic differentiation in culture of pure progenitors.

    abstract::Methodology has been developed that enables virtually complete purification and recovery of early hematopoietic progenitors from human adult blood, a minority of which is multipotent and endowed with self-renewal capacities, i.e., exhibits stem cell properties. This report briefly reviews: (i) the key steps involved i...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Pelosi E,Testa U,Gabbianelli M,Valtieri M,Montesoro E,Samoggia P,Mastroberardino G,Isacchi G,Peschle C

    更新日期:1992-11-01 00:00:00

  • Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.

    abstract::Plasma cell leukemia (PCL) is a rare and aggressive variant of myeloma characterized by the presence of circulating plasma cells. It is classified as either primary PCL occurring at diagnosis or as secondary PCL in patients with relapsed/refractory myeloma. Primary PCL is a distinct clinic-pathological entity with dif...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/leu.2012.336

    authors: Fernández de Larrea C,Kyle RA,Durie BG,Ludwig H,Usmani S,Vesole DH,Hajek R,San Miguel JF,Sezer O,Sonneveld P,Kumar SK,Mahindra A,Comenzo R,Palumbo A,Mazumber A,Anderson KC,Richardson PG,Badros AZ,Caers J,Cavo M,Le

    更新日期:2013-04-01 00:00:00

  • Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients.

    abstract::The presence of CD19 in myelomatous plasma cells (MM-PCs) correlates with adverse prognosis in multiple myeloma (MM). Although CD19 expression is upregulated by CD81, this marker has been poorly investigated and its prognostic value in MM remains unknown. We have analyzed CD81 expression by multiparameter flow cytomet...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2012.42

    authors: Paiva B,Gutiérrez NC,Chen X,Vídriales MB,Montalbán MÁ,Rosiñol L,Oriol A,Martínez-López J,Mateos MV,López-Corral L,Díaz-Rodríguez E,Pérez JJ,Fernández-Redondo E,de Arriba F,Palomera L,Bengoechea E,Terol MJ,de Paz R,Mar

    更新日期:2012-08-01 00:00:00

  • CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL.

    abstract::The presence of rare malignant stem cells supplying a hierarchy of malignant cells has recently been reported. In human acute myelogenous leukemia (AML), the leukemia stem cells (LSCs) have been phenotypically restricted within the CD34+CD38- fraction. To understand the origin of malignant cells in primary human B-pre...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2008.83

    authors: Kong Y,Yoshida S,Saito Y,Doi T,Nagatoshi Y,Fukata M,Saito N,Yang SM,Iwamoto C,Okamura J,Liu KY,Huang XJ,Lu DP,Shultz LD,Harada M,Ishikawa F

    更新日期:2008-06-01 00:00:00

  • Do CLL B cells correspond to naive or memory B-lymphocytes? Evidence for an active Ig switch unrelated to phenotype expression and Ig mutational pattern in B-CLL cells.

    abstract::Recent work suggests that chronic lymphocytic leukemia (B-CLL) expressing unmutated immunoglobulin V genes could correspond to the proliferation of naive B cells whereas those expressing mutated genes, may correspond to the proliferation of post-germinal center B cells. Current data from gene profiling expression have...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402731

    authors: Oppezzo P,Magnac C,Bianchi S,Vuillier F,Tiscornia A,Dumas G,Payelle-Brogard B,Ajchenbaum-Cymbalista F,Dighiero G,Pritsch O

    更新日期:2002-12-01 00:00:00

  • L-type amino-acid transporter 1 (LAT1): a therapeutic target supporting growth and survival of T-cell lymphoblastic lymphoma/T-cell acute lymphoblastic leukemia.

    abstract::The altered metabolism of cancer cells is a treasure trove to discover new antitumoral strategies. The gene (SLC7A5) encoding system L amino-acid transporter 1 (LAT1) is overexpressed in murine lymphoma cells generated via T-cell deletion of the pten tumor suppressor, and also in human T-cell acute lymphoblastic leuke...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2014.338

    authors: Rosilio C,Nebout M,Imbert V,Griessinger E,Neffati Z,Benadiba J,Hagenbeek T,Spits H,Reverso J,Ambrosetti D,Michiels JF,Bailly-Maitre B,Endou H,Wempe MF,Peyron JF

    更新日期:2015-06-01 00:00:00

  • In vitro effects of IL-2 on NK-activity, clonogenic potential, blast cell proliferation and cytokine release of MDS bone marrow patients.

    abstract::To evaluate the clinical usefulness of IL-2 in myelodysplastic syndromes (MDS) the in vitro effects of interleukin-2 (IL-2) on blast cell proliferation, clonogenic activity, cytokine release and cell mediated cytotoxicity were examined in 49 MDS patients. Morphological analyses of bone marrow (BM) cytospin preparation...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Cortelezzi A,Sarina B,Cattaneo C,Pomati M,Silvestris I,Soligo D,Calori R,Di Stefano M,Hu C,Monza M,Radelli L,Maiolo AT

    更新日期:1996-07-01 00:00:00

  • Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): long-term results of trials 82,85,89,92 and 97.

    abstract::In this study, the long-term outcome of 1818 patients treated in five consecutive clinical trials (the cooperative study group for childhood acute lymphoblastic leukaemia (COALL) 82, 85, 89, 92 and 97) from 24 cooperating centres in Germany is reported. The probability of event-free survival (pEFS) improved significan...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章

    doi:10.1038/leu.2009.249

    authors: Escherich G,Horstmann MA,Zimmermann M,Janka-Schaub GE,COALL study group.

    更新日期:2010-02-01 00:00:00

  • Translocations t(14;18) and t(8;14) with rearranged bcl-2 and c-myc in a case presenting as B-ALL (L3).

    abstract::Follicular lymphoma is a low grade malignancy characterized by the translocation t(14;18), which involves the putative oncogene bcl-2. We describe a 73-year-old patient presenting with Burkitt acute lymphoblastic leukemia (B-ALL) L3 (Burkitt type), whose cells had the following immunophenotype: CD19+, CD22+, HLA-DR+, ...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:

    authors: Brito-Babapulle V,Crawford A,Khokhar T,Laffan M,Matutes E,Fairhead S,Catovsky D

    更新日期:1991-01-01 00:00:00

  • Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia: results in patients treated in second molecular remission or with molecularly persistent disease.

    abstract::In all, 17 consecutive patients in hematological complete remission (HCR) of acute promyelocytic leukemia (APL) received allogeneic stem cell transplantation (SCT) from an HLA-identical sibling and were monitored by reverse transcriptase polymerase chain reaction of PML/RARalpha prior and after transplant. Median age ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403078

    authors: Lo-Coco F,Romano A,Mengarelli A,Diverio D,Iori AP,Moleti ML,De Santis S,Cerretti R,Mandelli F,Arcese W

    更新日期:2003-10-01 00:00:00

  • Cancer increases risk of in-hospital death from COVID-19 in persons

    abstract::The impact of cancer on outcome of persons with coronavirus disease 2019 (COVID-19) after infection with acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is controversial. We studied 1859 subjects with COVID-19 from seven centers in Wuhan, China, 65 of whom had cancer. We found having cancer was an independent ri...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-020-0986-7

    authors: Li Q,Chen L,Li Q,He W,Yu J,Chen L,Cao Y,Chen W,Di Wu,Dong F,Cai L,Ran Q,Li L,Liu Q,Ren W,Gao F,Wang H,Chen Z,Gale RP,Hu Y

    更新日期:2020-09-01 00:00:00

  • Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.

    abstract::The 2001 World Health Organization (WHO) treatise on the classification of hematopoietic tumors lists chronic myeloproliferative diseases (CMPDs) as a subdivision of myeloid neoplasms that includes the four classic myeloproliferative disorders (MPDs)-chronic myelogenous leukemia, polycythemia vera (PV), essential thro...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2404955

    authors: Tefferi A,Vardiman JW

    更新日期:2008-01-01 00:00:00

  • Clinical relevance of in vitro chemoresistance in childhood acute myeloid leukemia.

    abstract::To determine the clinical relevance of in vitro drug chemoresistance in childhood acute myeloid leukemia, we used an MTT assay to test leukemic cells from 132 newly diagnosed children. Patients were diagnosed according to the French-American-British (FAB) classification as follows: M0 (n = 12), M1 (n = 16), M2 (n = 53...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402305

    authors: Yamada S,Hongo T,Okada S,Watanabe C,Fujii Y,Ohzeki T

    更新日期:2001-12-01 00:00:00

  • Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report.

    abstract::Infants <1 year of age have a high prevalence of prognostically unfavorable leukemias and a presumed susceptibility to treatment-related toxicities. A total of 125 infants with acute myeloid leukemia (AML) were treated in studies AML-BFM-98 (n = 59) and -2004 (n = 66). Treatment regimens of both studies were comparabl...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2011.267

    authors: Creutzig U,Zimmermann M,Bourquin JP,Dworzak MN,Kremens B,Lehrnbecher T,von Neuhoff C,Sander A,von Stackelberg A,Schmid I,Starý J,Steinbach D,Vormoor J,Reinhardt D

    更新日期:2012-04-01 00:00:00

  • Impact of PTEN abnormalities on outcome in pediatric patients with T-cell acute lymphoblastic leukemia treated on the MRC UKALL2003 trial.

    abstract::PTEN gene inactivation by mutation or deletion is common in pediatric T-cell acute lymphoblastic leukemia (T-ALL), but the impact on outcome is unclear, particularly in patients with NOTCH1/FBXW7 mutations. We screened samples from 145 patients treated on the MRC UKALL2003 trial for PTEN mutations using heteroduplex a...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2015.206

    authors: Jenkinson S,Kirkwood AA,Goulden N,Vora A,Linch DC,Gale RE

    更新日期:2016-01-01 00:00:00

  • Four subclones with distinct immunoglobulin light chain phenotypes. (kappa+lambda+, kappa+, lambda+ and kappa-lambda-) from acute leukemia.

    abstract::A human acute lymphoblastic leukemia (ALL) cell line, BALM-9, was established from the peripheral blood specimen of a immunoglobin (lg) phenotype, the established BALM-9 cell line expressed both kappa and lambda light (L) chains simultaneously in a range of 30-80%. Two-color flow cytometric analysis demonstrated that ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Matsuo Y,Nakamura S,Ariyasu T,Terao R,Imajyo K,Tsubota T,Kuwahara K,Sakaguchi N

    更新日期:1996-04-01 00:00:00

  • VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma.

    abstract::Bortezomib (V) was combined with thalidomide (T) and dexamethasone (D) in a phase I/II trial to determine dose-limiting toxicities (DLT's) and clinical activity of the VTD regimen in 85 patients with advanced and refractory myeloma. The starting dose of V was 1.0 mg/m(2) (days 1, 4, 8, 11, every 21 day) with T added f...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2008.99

    authors: Pineda-Roman M,Zangari M,van Rhee F,Anaissie E,Szymonifka J,Hoering A,Petty N,Crowley J,Shaughnessy J,Epstein J,Barlogie B

    更新日期:2008-07-01 00:00:00

  • Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.

    abstract::The majority of chronic phase chronic myeloid leukemia (CML) patients treated with the tyrosine kinase inhibitor (TKI) imatinib mesylate maintain durable responses to the drug. However, most patients relapse after withdrawal of imatinib and advanced stage patients often develop drug resistance. As CML is considered a ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404638

    authors: Brendel C,Scharenberg C,Dohse M,Robey RW,Bates SE,Shukla S,Ambudkar SV,Wang Y,Wennemuth G,Burchert A,Boudriot U,Neubauer A

    更新日期:2007-06-01 00:00:00

  • The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells.

    abstract::We have investigated the activity of ITF2357, a novel hydroxamate histone deacetylase inhibitor, on multiple myeloma (MM) and acute myelogenous leukemia (AML) cells in vitro and in vivo. ITF2357 induced apoptosis in 8/9 MM and 6/7 AML cell lines, as well as 4/4 MM and 18/20 AML freshly isolated cases, with a mean IC(5...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404860

    authors: Golay J,Cuppini L,Leoni F,Micò C,Barbui V,Domenghini M,Lombardi L,Neri A,Barbui AM,Salvi A,Pozzi P,Porro G,Pagani P,Fossati G,Mascagni P,Introna M,Rambaldi A

    更新日期:2007-09-01 00:00:00

  • HTLV-1-like particles and HTLV-1-related DNA sequences in an unambiguous case of Sèzary syndrome.

    abstract::An unambiguous case of Sèzary syndrome associated with the presence of unusual retroviral infection markers is described. The blood smear showed 15% typical Sèzary cells but also rare atypical lymphocytes with convoluted nuclei, evocative of characteristic adult T-cell leukemia (ATL) flower cells. However, the patient...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Bazarbachi A,Saal F,Laroche L,Lasneret J,Gessain A,Daniel MT,Périès J

    更新日期:1994-01-01 00:00:00

  • Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98-3936.

    abstract::Polymerase chain reaction (PCR) assessment of clonal T-cell receptor (TCR) and immunoglobulin (Ig) gene rearrangements is an important diagnostic tool in mature T-cell neoplasms. However, lack of standardized primers and PCR protocols has hampered comparability of data in previous clonality studies. To obtain referenc...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404481

    authors: Brüggemann M,White H,Gaulard P,Garcia-Sanz R,Gameiro P,Oeschger S,Jasani B,Ott M,Delsol G,Orfao A,Tiemann M,Herbst H,Langerak AW,Spaargaren M,Moreau E,Groenen PJ,Sambade C,Foroni L,Carter GI,Hummel M,Bastard C,D

    更新日期:2007-02-01 00:00:00

  • Allelotype analysis of the myelodysplastic syndrome.

    abstract::Myelodysplastic syndromes (MDS) are a group of clonal hematologic disorders found predominantly in the elderly. The molecular mechanisms underlying the development of MDS remain obscure. In order to begin to identify tumor suppressor genes involved in these disorders, we performed a detailed microsatellite allelotype ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401717

    authors: Xie D,Hofmann WK,Mori N,Miller CW,Hoelzer D,Koeffler HP

    更新日期:2000-05-01 00:00:00

  • Role of DNA methylation for expression of novel stem cell marker CDCP1 in hematopoietic cells.

    abstract::CDCP1, a novel stem cell marker, is expressed in hematopoietic cell line K562 but not in Jurkat. When CDCP1 promoter was transfected exogenously, Jurkat showed comparable promoter activity with K562, suggesting that the factor to enhance transcription was present but interfered to function in Jurkat. The reporter assa...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404312

    authors: Kimura H,Morii E,Ikeda JI,Ezoe S,Xu JX,Nakamichi N,Tomita Y,Shibayama H,Kanakura Y,Aozasa K

    更新日期:2006-09-01 00:00:00

  • Treatment and unmet needs in steroid-refractory acute graft-versus-host disease.

    abstract::Acute graft-versus-host disease (aGVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (alloHCT) and is a major cause of morbidity and mortality. Systemic steroid therapy is the first-line treatment for aGVHD, although about half of patients will become refractory to treatment. As the n...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/s41375-020-0804-2

    authors: Malard F,Huang XJ,Sim JPY

    更新日期:2020-05-01 00:00:00

  • Therapeutic targeting of CK2 in acute and chronic leukemias.

    abstract::CK2 is a ubiquitously expressed, constitutively active Ser/Thr protein kinase, which is considered the most pleiotropic protein kinase in the human kinome. Such a pleiotropy explains the involvement of CK2 in many cellular events. However, its predominant roles are stimulation of cell growth and prevention of apoptosi...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/leu.2017.301

    authors: Buontempo F,McCubrey JA,Orsini E,Ruzzene M,Cappellini A,Lonetti A,Evangelisti C,Chiarini F,Evangelisti C,Barata JT,Martelli AM

    更新日期:2018-01-01 00:00:00

  • Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV.

    abstract::Major molecular remission (MMR) is an important therapy goal in chronic myeloid leukemia (CML). So far, MMR is not a failure criterion according to ELN management recommendation leading to uncertainties when to change therapy in CML patients not reaching MMR after 12 months. At monthly landmarks, for different molecul...

    journal_title:Leukemia

    pub_type: 杂志文章,随机对照试验

    doi:10.1038/s41375-018-0055-7

    authors: Saussele S,Hehlmann R,Fabarius A,Jeromin S,Proetel U,Rinaldetti S,Kohlbrenner K,Einsele H,Falge C,Kanz L,Neubauer A,Kneba M,Stegelmann F,Pfreundschuh M,Waller CF,Oppliger Leibundgut E,Heim D,Krause SW,Hofmann WK,Has

    更新日期:2018-05-01 00:00:00